Psychedelic drugs that were only a few decades ago relegated to experimentation in only the dorm rooms have now made their way back in the labs for a 21st century upgrade.
Scientists are now beginning to rediscover their many astonishing therapeutic advantages and uses for a wide range of issues ranging from issues like depression and drug addiction to issues like acceptance of mortality.
Due to its great, well deserved hype, last year in 2019, Johns Hopkins University, United States’ oldest research university decided to launch a center as well for the psychedelic studies. This centre was the first in the country and also the world’s largest.
With work being done at a good pace, the center aims to enforce strict standards of scientific rigor in the field about which many feel that it has veered close to mysticism and that it has also relied heavily on the subjective reports.
The head of the facility, Roland Griffiths, has led some very promising studies that were performed on psilocybin for the treatment of both depression and alcoholism. He added his opinions on the subject saying that the most remarkable thing about working with psychedelics is that they are very much likely to have the trans-diagnostic applicability.
Griffiths also added that psychedelics not only hold a high hope for the treatment of many mental disorders but also provide a great opportunity to look into the neuroscience of how these substances affect the brain activity and the worldview and that he believes is ultimately very healthy.
Griffiths and his colleagues in fact helped in reviving the field of Psychedelics around the year 2000, long after the work on it had been seized, when they managed to get the government’s approval on giving high doses of the drug psilocybin to healthy volunteers.